Pfizer Inc. (PFE)
Pfizer CEO plans to meet activist investor Starboard Value, FT reports
Pfizer CEO Albert Bourla plans to meet activist investor Starboard Value, the Financial Times reported on Tuesday, citing people familiar with the matter.
Healthy Returns: What activist Starboard's $1 billion stake means for Pfizer
Pfizer's troubles may finally be coming to a head. Meanwhile, Hims & Hers is joining S&P SmallCap 600.
Pfizer Receives $1 Billion From Starboard Value, Stock Rises
PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the struggling pharma giant.
Pfizer Stock Soars as Activist Investor Starboard Takes $1 Billion Stake
Pfizer's (PFE, Financial) stock experienced a boost on Monday, surging by 3 %, following the news that activist investor Starboard Value has acquired a substantial stake in the pharmaceutical giant. The investment, valued at approximately $1 billion, could regain investor confidence in Pfizer.
Pfizer (PFE) Shares Rise on Starboard Value's $1 Billion Investment
Pfizer's (PFE, Financial) stock saw an uptick after reports emerged that activist investor Starboard Value has invested $1 billion in the pharmaceutical giant. This development was positively received not only by equity investors but also by bondholders, as evidenced by a narrowing spread on the company's outstanding bonds.
Pfizer's bondholders cheer news of activist investor Starboard's $1 billion investment
Pfizer Inc.'s stock gained Monday after a report that activist investor Starboard Value has invested $1 billion in the drug company. Bondholders seem to like the news too.
Pfizer CEO's Job Is at Risk. A Shot of Discipline Could Help.
As activist Starboard teams up with former Pfizer executives, the pharma giant's lack of focus is in the spotlight.
Watch These Pfizer Price Levels as Stock Gains After Report of Starboard Taking Stake
Pfizer (PFE) shares have gained ground since theThe Wall Street Journal reported over the weekend that activist investor Starboard Value has taken a roughly $1 billion stake in the drug maker and is pushing for changes at the company.
Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential
Pfizer, yielding 5.6%, is an Ultra SWAN bargain with upside potential in the next year. Despite $70 billion in debt, Pfizer's A- credit rating and stable cash flow ensure long-term stability and very strong dividend safety. Pfizer's growth outlook includes a 5% long-term growth rate, with a 10% to 11% long-term return potential.
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
Pfizer: A Strong Product Pipeline Could Lead To Significant Upside
Pfizer's stock has likely bottomed and shows strong technical and fundamental indicators, including a "Golden Cross" and robust cost reduction plans. The company's promising pipeline, including weight-loss treatments and AI-driven drug discovery, offers significant long-term upside potential. The Seagen acquisition enhances Pfizer's cancer treatment portfolio, positioning it well in a high-demand sector.
Why Pfizer Will Find It Hard to Appease Its Activist Investor
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
